Search InvestCenter

Recent Quotes

My Watchlist

Top Indices

Articles published by Santhera Pharmaceuticals Holding AG

< Previous 1 2 Next >

Santhera Announces Positive Topline Results from LIONHEART Study with AGAMREE® (vamorolone) Demonstrating Unique Mineralocorticoid Receptor Antagonism

October 01, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy

September 24, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update

September 12, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe

September 10, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Closes Financings and Secures Funds to Reach Break-Even Expected in 2026

August 13, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary

July 31, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting

June 18, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow Break-Even

June 18, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Announces Launch of Early Access Program in China for AGAMREE® by its Partner Sperogenix

June 10, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Publishes Agenda for its Annual General Meeting

May 28, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Publishes Annual Report 2023

May 28, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

April 25, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA

March 27, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States

March 14, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology

February 14, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy

January 15, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom

January 12, 2024

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy

December 18, 2023

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage

December 07, 2023

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

October 27, 2023

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

October 13, 2023

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update

September 07, 2023

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group

July 31, 2023

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone

July 19, 2023

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Publishes Timeline of the Reverse Share Split

June 29, 2023

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Shareholders Approve all Board Proposals at Today’s Annual General Meeting

June 27, 2023

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties

June 20, 2023

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Publishes Agenda for its Annual General Meeting

June 06, 2023

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Publishes Annual Report 2022

May 31, 2023

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

Santhera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update

April 27, 2023

From Santhera Pharmaceuticals Holding AG

Via GlobeNewswire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

© 2025 FinancialContent. All rights reserved.